Search clinical trials for: Atrovastatin and Ezetimibe combination therapy

Total 16587 results

Abbott

Completed

A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe

Pharmacokinetics

United States
Organon and Co

Completed

IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

Myocardial Infarction | Hypercholesterolemia
Organon and Co

Completed

Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)

Hypercholesterolemia
Organon and Co

Completed

Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)

Coronary Disease | Hypercholesterolemia | Atherosclerotic Disease
Organon and Co

Completed

A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)

Hypercholesterolemia
Aegerion Pharmaceuticals, Inc.

Completed

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

Hyperlipidemia

United States
Yonsei University

Completed

Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia

Hyperlipidemia

Korea, Republic of
Organon and Co

Completed

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

Hypercholesterolemia
Organon and Co

Completed

Eze/Simva Switch Study in Diabetics (0653A-807)

Diabetes Mellitus, Type 2
Organon and Co

Terminated

Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)

Cardiovascular Diseases | Diabetes Mellitus
Zhejiang Hisun Pharmaceutical Co. Ltd.

Unknown

Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia (HS-25-C-01)

Primary Hypercholesterolemia
Organon and Co

Completed

Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)

Diabetes Mellitus | Cardiovascular Disorder
University at Buffalo
Kaleida Health

Completed

To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects

Inflammation

United States
Penza State University

Recruiting

Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI (CONTRAST-2)

Quality of Life | Arterial Stiffness | Myocardial Infarction, Acute | Myocardial Strain

Russian Federation
Complexa, Inc.

Completed

A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males (DDI)

Acute Kidney Injury

United States
Organon and Co

Completed

Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)

Familial Hypercholesterolemia
Veloxis Pharmaceuticals

Completed

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

Dyslipidemia

United States
Fundación para el Fomento de la Investigación Sanitaria...

Completed

Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia

Dyslipidemia
Organon and Co

Withdrawn

A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406) (VYCTORY)

Dyslipidemia
University of Colorado, Denver
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Merck...

Completed

Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes

Dyslipidemia | Type 1 Diabetes Mellitus

United States
Organon and Co

Completed

A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)

Type 2 Diabetes Mellitus | Hypercholesterolemia
Organon and Co
PT. Schering-Plough. Tbk Indonesia

Completed

Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)

Hypercholesterolemia | Coronary Arteriosclerosis
University Clinical Centre of Republic of Srpska

Recruiting

Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry (RS-ACS)

Dyslipidemias | Acute Coronary Syndrome

Bosnia and Herzegovina
Organon and Co

Completed

Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)

Hypercholesterolemia
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY EAST)

Hypercholesterolemia

China, India, Thailand
Baylor College of Medicine
Merck Sharp & Dohme LLC

Completed

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. (Merck-123)

Metabolic Syndrome

United States
University of Maryland, Baltimore
Merck Sharp & Dohme LLC

Completed

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

Metabolic Syndrome

United States
Brasilia Heart Study Group

Completed

Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction

Myocardial Infarction

Brazil
Organon and Co
Schering-Plough

Completed

The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)

Coronary Disease | Hypercholesterolemia
Seoul National University Bundang Hospital
Yuhan Corporation

Completed

Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin

Cardiovascular Diseases

Korea, Republic of
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge

Active, not recruiting

Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease (INTENSITY-HIGH)

Cardiovascular Diseases | Atherosclerosis

United Kingdom
Solvay Pharmaceuticals

Completed

A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome

Hyperlipidemia Combined

Belgium, France, Germany
Sunnybrook Health Sciences Centre
Merck Frosst Canada Ltd.; Schering-Plough

Terminated

INdians Followed for INtensive Lipid Lowering Treatment and Its safetY (INFINITY)

Hypercholesterolemia

Canada
Organon and Co

Completed

Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)

Hypercholesterolemia
Hue University of Medicine and Pharmacy
Università degli Studi di Sassari

Unknown

Lipid-lowering Therapies in Vietnamese Chronic Kidney Disease Population (VietCKD)

Chronic Kidney Diseases | Hypercholesterolemia

Vietnam
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR); Biovalorem

Active, not recruiting

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

Pancreatic Cancer | Metastatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer

Canada
Queen's University

Completed

Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy

Dyslipidemia | Vascular Disease

Canada
National Cheng-Kung University Hospital

Completed

Vascular Effects of Ezetimibe/Simvastatin and Simvastatin on Atherosclerosis

Atherosclerosis

Taiwan
Organon and Co

Completed

Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)

Hypercholesterolemia
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3)

Hyperlipidemia

Canada, Denmark, France, United States, Czechia, New Zealand, Australia, South Africa, Italy, United Kingdom, Netherlands, Germany, Norway
Yonsei University

Not yet recruiting

Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)

Peripheral Artery Disease | Polyvascular Disease

Korea, Republic of
University of Palermo

Completed

Ultrasound Therapy and Manual Therapy in Digital Ischemic Ulcers

Systemic Sclerosis

Italy
Makerere University
University of Oxford; Case Western Reserve University

Unknown

Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial (STAR)

HIV Infection
Organon and Co

Completed

To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Hypercholesterolemia
Sanofi
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Hypercholesterolemia

France, Belgium, Austria, Canada, Czechia, Denmark, Finland, Germany, Greece, Hungary, Poland, Romania, Slovakia, Slovenia, Spain, Switzerland
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Hypercholesterolemia

United States
Instituto Nacional de Ciencias Medicas y Nutricion...
Merck Sharp & Dohme LLC

Withdrawn

Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors

Cardiovascular Diseases | Hyperlipidemia
Organon and Co

Completed

Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)

Metabolic Syndrome | Hypercholesterolemia
Allergan

Completed

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy

Ocular Hypertension | Glaucoma, Open-Angle

Spain
Organon and Co

Completed

A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)

Hypercholesterolemia

3

Subscribe